1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Strides Pharma Science Limited

Strides Pharma Science Limited

STAR.BO
Strides Pharma Science LimitedIN flagBombay Stock Exchange
1,121.50
INR
-5.40
- -
103.36BMarket Cap
Strides Pharma Science Limited
STAR.BO
(Bombay Stock Exchange)

Recent

price

1,121.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
325.42
361.64
431.33
152.09
189.94
333.13
297.24
312.53
235.44
296.67
362.81
336.73
400.49
409.88
496.18
- -
502.97
Revenue per Share
27.36
26.11
38.55
144.3
141.85
13.14
44.73
74.26
36.25
4.06
29.96
-51.28
-22.49
-7.76
390.55
- -
37.1
Basic EPS, GAAP
-10.34
33.54
37.42
22.89
14
-35.83
-44.11
-24.09
6.71
22.87
53.73
-28.73
4.93
77.04
74.38
- -
- -
Free Cash Flow per Basic Share
0.12
1.62
1.73
2
110.01
2.98
4.84
4.95
2
17.18
2
2.5
- -
1.49
2.5
- -
- -
Dividend per Share
22.29
64.3
86.58
10.03
-51.55
-5.67
34.45
25.13
52.54
36.18
64.13
10.26
-12.21
-21.16
59.89
- -
- -
Book Value per Share
-26.96
-18.22
-185.97
-17.7
147.47
54.41
23.69
9.15
-9.45
180.88
191.38
141.78
121.67
111.56
159.97
- -
- -
Tangible Book Value per Share
40
47
58
59
60
83
89
89
90
90
90
90
90
91
92
- -
92
Basic Weighted Avg Shares
13,048
16,958
25,116
8,919
11,315
27,512
26,564
27,965
21,083
26,567
32,512
30,221
36,077
37,300
45,653
48,587
46,307
Sales/Revenue/Turnover
12.36
14
16.58
14.28
15.83
10.47
16.19
8.88
6.56
13.79
12.96
-8
3.96
8.61
13.37
14.88
13.74
Operating Margin (%)
493
639
1,043
1,095
640
1,520
1,987
1,939
1,718
1,878
2,063
2,330
2,433
2,207
1,923
2,024
1,946
Depreciation Expense
1,097
1,224
2,245
8,462
8,450
1,085
3,997
6,645
3,246
364
2,684
-4,602
-2,026
-706
35,935
5,562
3,416
Net Income, GAAP
15.32
24.25
14.15
1.54
35.83
26.43
18.48
7.11
- -
20.71
11.49
- -
- -
- -
15.92
14.09
17.49
Effective Tax Rate (%)
8.41
7.22
8.94
94.88
74.68
3.94
15.05
23.76
15.4
1.37
8.26
-15.23
-5.62
-1.89
78.71
11.45
7.38
Profit Margin (%)
2,661
10,368
-11,665
-3,864
4,429
16,236
6,880
5,867
3,889
-1,702
815
-473
2,557
932
5,102
7,178
- -
Working Capital
14,569
20,098
10,543
7,311
2,548
26,285
16,377
15,591
18,149
8,577
10,928
10,221
13,435
7,431
6,227
6,042
- -
LT Debt
10,896
15,553
14,169
20,981
11,697
27,081
28,874
26,183
28,017
25,947
28,140
23,833
21,729
20,717
25,865
31,493
- -
Total Equity
6.15
5.88
9.38
3.24
3.97
5.05
5.74
4.18
- -
5.32
7.45
- -
- -
- -
11.27
13.15
- -
Return on Invested Capital (%)
5.82
9.44
12.77
37.34
74.89
11.59
13.36
24.23
- -
2.05
14.21
- -
- -
- -
160.42
31.73
290.64
Return on Capital (%)
122.83
62.65
55.72
300.65
- -
- -
- -
249.47
93.37
9.16
59.75
-138.05
- -
- -
- -
172.93
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
12,569
- -
LT Borrowings
- -
5,712
- -
LT Finance Leases
- -
515
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
92
- -
Market Capitalization
60,678
61,554
82,774

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
31,017
- -
Cash, Cash Equivalents & STI
- -
1,986
- -
Accounts Receivable, Net
- -
12,029
- -
Inventories
- -
12,776
- -
Total Current Liabilities
- -
25,915
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
12,569
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.32%
3.56%
21.76%
Free Cash Flow
144.42%
241.61%
2.65%
Net Income, GAAP
-483.38%
-1,133.22%
-84.52%
Sales/Revenue/Turnover
7.01%
8.91%
6.43%
Total Cash Common Dividend
- -
- -
60.35%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,300
9,994
10,058
9,239
37,300
2025
10,543
11,669
11,537
11,904
45,653
2026
11,197
11,946
13,235
- -
48,587

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.79
-14.54
5.43
- -
-7.76
2025
364.65
7.81
9.56
8.92
390.55
2026
10.81
21.93
13.77
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.49
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS)
Takeda Pharmaceutical Company Limited (4502.T)
CBD Global Sciences Inc. (CBDN.CN)
Lupin Limited (LUPIN.NS)
Sunset Island Group, Inc. (SIGO)
Organogenesis Holdings Inc. (ORGO)
Business
Strides Pharma Science Limited (STAR.BO) is an integrated global pharmaceutical company focused on the development, manufacturing, and marketing of a diverse portfolio of branded and generic dosage forms. The company offers differentiated and high-barrier-to-entry generic products, including sterile injectables, softgels, delayed and controlled release formulations, and complex generics; institutional business products such as pre-filled syringes, ampoules, vials, lyophilized and powder injectables, and ophthalmics; and over-the-counter (OTC) products along with APIs (active pharmaceutical ingredients). Its offerings span tablets, capsules, liquids, ointments, creams, and specialized delivery systems like extended-release and abuse-deterrent formulations, primarily targeting therapeutic areas including oncology, anti-infectives, cardiovascular, gastroenterology, and ophthalmology. Strides operates across regulated markets such as the United States and Europe, as well as emerging markets in Latin America, Africa, and Asia-Pacific, with manufacturing facilities in India and subsidiaries worldwide. Founded in 1990 and headquartered in Bengaluru, India, the company maintains a global footprint through its network of facilities approved by major regulators like USFDA, MHRA, and TGA. Strides serves institutional customers, including hospitals and government tenders, alongside retail and branded generic channels in emerging economies. In recent developments, Strides completed the acquisition of BDR Pharmaceuticals' Injectables business in 2023, significantly bolstering its sterile injectables portfolio and US market presence; launched several high-value generic products, including complex generics for the US market; and entered strategic partnerships for biosimilars and novel drug delivery technologies. The company also raised capital through qualified institutional placements and announced expansions in its US-focused sterile manufacturing capabilities at a new facility in Bengaluru. These initiatives underscore Strides' strategic shift toward high-margin sterile injectables and biosimilars amid ongoing growth in regulated markets.